HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial-Reference-Cited by-同舟云学术

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

Published:2017-04 Issue:4 Volume:18 Page:545-554
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Llombart-Cussac Antonio,Cortés Javier,Paré Laia,Galván Patricia,Bermejo Begoña,Martínez Noelia,Vidal Maria,Pernas Sònia,López Rafael,Muñoz Montserrat,Nuciforo Paolo,Morales Serafín,Oliveira Mafalda,de la Peña Lorena,Peláez Alexandra,Prat Aleix

Publisher

Elsevier BV

Subject

Oncology

Reference44 articles.

1. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy;Arpino;J Natl Cancer Inst,2007

2. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts;Rimawi;Clin Cancer Res,2011

3. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer;Baselga;N Engl J Med,2012

4. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study;Blackwell;J Clin Oncol,2012

5. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study;Swain;Lancet Oncol,2013

Cited by 262 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

2. Personalized treatment using predictive biomarkers in solid organ malignancies: A review;Tumori Journal;2024-08-02

3. HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial;Clinical Cancer Research;2024-07-12

4. Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies;npj Breast Cancer;2024-06-29

5. The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer;npj Breast Cancer;2024-06-19